Switch to:
Also traded in: Germany, South Africa

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.25
APNHF's Cash to Debt is ranked lower than
82% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. APNHF: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
APNHF' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.44 Max: 128.44
Current: 0.25
0.22
128.44
Equity to Asset 0.41
APNHF's Equity to Asset is ranked lower than
79% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. APNHF: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
APNHF' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.47 Max: 0.71
Current: 0.41
0.25
0.71
Interest Coverage 4.50
APNHF's Interest Coverage is ranked lower than
83% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. APNHF: 4.50 )
Ranked among companies with meaningful Interest Coverage only.
APNHF' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 4.82 Max: 5.91
Current: 4.5
3.11
5.91
F-Score: 5
Z-Score: 2.44
M-Score: -2.45
WACC vs ROIC
10.01%
8.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 25.28
APNHF's Operating margin (%) is ranked higher than
87% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. APNHF: 25.28 )
Ranked among companies with meaningful Operating margin (%) only.
APNHF' s Operating margin (%) Range Over the Past 10 Years
Min: 23.27  Med: 25.66 Max: 26.74
Current: 25.28
23.27
26.74
Net-margin (%) 12.08
APNHF's Net-margin (%) is ranked higher than
69% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. APNHF: 12.08 )
Ranked among companies with meaningful Net-margin (%) only.
APNHF' s Net-margin (%) Range Over the Past 10 Years
Min: 12.08  Med: 18.03 Max: 20.82
Current: 12.08
12.08
20.82
ROE (%) 10.77
APNHF's ROE (%) is ranked higher than
63% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. APNHF: 10.77 )
Ranked among companies with meaningful ROE (%) only.
APNHF' s ROE (%) Range Over the Past 10 Years
Min: 10.77  Med: 20.48 Max: 38.57
Current: 10.77
10.77
38.57
ROA (%) 4.33
APNHF's ROA (%) is ranked higher than
54% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. APNHF: 4.33 )
Ranked among companies with meaningful ROA (%) only.
APNHF' s ROA (%) Range Over the Past 10 Years
Min: 4.33  Med: 9.51 Max: 12.24
Current: 4.33
4.33
12.24
ROC (Joel Greenblatt) (%) 32.89
APNHF's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. APNHF: 32.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
APNHF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 32.89  Med: 63.55 Max: 146.66
Current: 32.89
32.89
146.66
Revenue Growth (3Y)(%) 22.60
APNHF's Revenue Growth (3Y)(%) is ranked higher than
85% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. APNHF: 22.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
APNHF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 15  Med: 23.3 Max: 33.4
Current: 22.6
15
33.4
EBITDA Growth (3Y)(%) 22.60
APNHF's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. APNHF: 22.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
APNHF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 24.1 Max: 46.5
Current: 22.6
0
46.5
EPS Growth (3Y)(%) 7.00
APNHF's EPS Growth (3Y)(%) is ranked lower than
52% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. APNHF: 7.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
APNHF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 7  Med: 26.6 Max: 365.5
Current: 7
7
365.5
GuruFocus has detected 5 Warning Signs with Aspen Pharmacare Holdings Ltd $APNHF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» APNHF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:OTCPK:MTZPY, OTCPK:SFOSF, NYSE:PRGO, OTCPK:HLUYY, NYSE:RDY, OTCPK:IPSEY, OTCPK:MKGAY, OTCPK:HKMPY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, OTCPK:ESALY, NAS:OPK, NYSE:TARO, OTCPK:SGIOF, NYSE:PTHN, NAS:NBIX, OTCPK:STDAF, NAS:MDCO, NYSE:CTLT » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Aspen Pharmacare Holdings Ltd through its subsidiaries, is engaged in manufacturing, marketing and distribution of branded and generic pharmaceutical, as well as nutritional products.

Aspen Pharmacare Holdings Ltd is a pharmaceutical company. The Company, through its subsidiaries, is engaged in the manufacture, marketing and distribution of branded and generic pharmaceutical, as well as consumer, OTC and nutritional products in selected territories, operating primarily in the healthcare industry. Its product types includes tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients. The Company operates in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America.

Ratios

vs
industry
vs
history
P/E(ttm) 30.56
APNHF's P/E(ttm) is ranked lower than
57% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. APNHF: 30.56 )
Ranked among companies with meaningful P/E(ttm) only.
APNHF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.7  Med: 20.57 Max: 40.2
Current: 30.56
12.7
40.2
PE(NRI) 30.56
APNHF's PE(NRI) is ranked lower than
56% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. APNHF: 30.56 )
Ranked among companies with meaningful PE(NRI) only.
APNHF' s PE(NRI) Range Over the Past 10 Years
Min: 12.99  Med: 22.04 Max: 40.2
Current: 30.56
12.99
40.2
P/B 3.10
APNHF's P/B is ranked lower than
51% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. APNHF: 3.10 )
Ranked among companies with meaningful P/B only.
APNHF' s P/B Range Over the Past 10 Years
Min: 2.66  Med: 4.42 Max: 8.41
Current: 3.1
2.66
8.41
P/S 3.70
APNHF's P/S is ranked lower than
55% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. APNHF: 3.70 )
Ranked among companies with meaningful P/S only.
APNHF' s P/S Range Over the Past 10 Years
Min: 2.27  Med: 3.83 Max: 6.78
Current: 3.7
2.27
6.78
PFCF 329.70
APNHF's PFCF is ranked lower than
95% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. APNHF: 329.70 )
Ranked among companies with meaningful PFCF only.
APNHF' s PFCF Range Over the Past 10 Years
Min: 22.73  Med: 86.76 Max: 433.79
Current: 329.7
22.73
433.79
POCF 41.20
APNHF's POCF is ranked lower than
78% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. APNHF: 41.20 )
Ranked among companies with meaningful POCF only.
APNHF' s POCF Range Over the Past 10 Years
Min: 14.81  Med: 24.97 Max: 54.21
Current: 41.2
14.81
54.21
EV-to-EBIT 20.29
APNHF's EV-to-EBIT is ranked higher than
51% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. APNHF: 20.29 )
Ranked among companies with meaningful EV-to-EBIT only.
APNHF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 15.4 Max: 29.6
Current: 20.29
6.8
29.6
EV-to-EBITDA 17.67
APNHF's EV-to-EBITDA is ranked lower than
53% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. APNHF: 17.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
APNHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.9 Max: 28.1
Current: 17.67
6.8
28.1
PEG 1.10
APNHF's PEG is ranked higher than
67% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. APNHF: 1.10 )
Ranked among companies with meaningful PEG only.
APNHF' s PEG Range Over the Past 10 Years
Min: 0.37  Med: 0.96 Max: 2.28
Current: 1.1
0.37
2.28
Shiller P/E 43.12
APNHF's Shiller P/E is ranked higher than
54% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. APNHF: 43.12 )
Ranked among companies with meaningful Shiller P/E only.
APNHF' s Shiller P/E Range Over the Past 10 Years
Min: 39.99  Med: 61.12 Max: 90.84
Current: 43.12
39.99
90.84
Current Ratio 1.76
APNHF's Current Ratio is ranked lower than
65% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. APNHF: 1.76 )
Ranked among companies with meaningful Current Ratio only.
APNHF' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.32 Max: 1.95
Current: 1.76
0.7
1.95
Quick Ratio 1.08
APNHF's Quick Ratio is ranked lower than
73% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. APNHF: 1.08 )
Ranked among companies with meaningful Quick Ratio only.
APNHF' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.97 Max: 1.31
Current: 1.08
0.49
1.31
Days Inventory 264.42
APNHF's Days Inventory is ranked lower than
90% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. APNHF: 264.42 )
Ranked among companies with meaningful Days Inventory only.
APNHF' s Days Inventory Range Over the Past 10 Years
Min: 115.22  Med: 143.67 Max: 264.42
Current: 264.42
115.22
264.42

Buy Back

vs
industry
vs
history
Dividend Growth (3y) 11.20
APNHF's Dividend Growth (3y) is ranked higher than
56% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. APNHF: 11.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
APNHF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 11.2 Max: 63.4
Current: 11.2
0
63.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.68
APNHF's Price/Projected FCF is ranked lower than
51% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. APNHF: 2.68 )
Ranked among companies with meaningful Price/Projected FCF only.
APNHF' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.15  Med: 3.82 Max: 5.84
Current: 2.68
2.15
5.84
Price/DCF (Earnings Based) 1.07
APNHF's Price/DCF (Earnings Based) is ranked higher than
69% of the 78 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. APNHF: 1.07 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.96
APNHF's Price/Median PS Value is ranked higher than
66% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. APNHF: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
APNHF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 0.89 Max: 1.4
Current: 0.96
0.39
1.4
Price/Peter Lynch Fair Value 1.22
APNHF's Price/Peter Lynch Fair Value is ranked higher than
62% of the 168 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. APNHF: 1.22 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
APNHF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 0.99 Max: 1.81
Current: 1.22
0.54
1.81
Earnings Yield (Greenblatt) (%) 4.90
APNHF's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. APNHF: 4.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
APNHF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.4  Med: 6.5 Max: 14.8
Current: 4.9
3.4
14.8
Forward Rate of Return (Yacktman) (%) 28.47
APNHF's Forward Rate of Return (Yacktman) (%) is ranked higher than
83% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. APNHF: 28.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
APNHF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.6  Med: 26.9 Max: 38.7
Current: 28.47
1.6
38.7

More Statistics

Revenue (TTM) (Mil) $2,369
EPS (TTM) $ 0.63
Beta1.65
Short Percentage of Float0.00%
52-Week Range $18.76 - 72.66
Shares Outstanding (Mil)455.85
» More Articles for APNHF

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Gains 5 New Stocks Feb 01 2017 

More From Other Websites
Europe faces steep price increases for some old cancer drugs Jan 28 2017
Aspen Pharmacare Holdings Ltd. breached its 50 day moving average in a Bullish Manner : APNHF-US :... Jan 12 2017
Aspen Pharmacare Holdings Ltd. breached its 50 day moving average in a Bullish Manner : APNHF-US :... Dec 30 2016
Aspen Pharmacare Holdings Ltd. : At a good price point right now? Dec 20 2016
Glaxo Sells Stake in South Africa’s Aspen for $619 Million Sep 28 2016
South Africa's Aspen Pharmacare FY profit drops 23 percent Sep 14 2016
Aspen Pharmacare moves into China as South Africa sales dip Sep 14 2016
Aspen Targets Further Chinese Acquisitions After Glaxo Deal Sep 14 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 mln Sep 12 2016
Aspen Tumbles Most in Two Years on Venezuela Loss, Disposals Sep 07 2016
Aspen Expands in China as African Drugmaker Targets Growth Jul 19 2016
AstraZeneca sells rights to anesthetics for up to $770 million Jun 09 2016
AstraZeneca sells rights to anaesthetics for up to $770 mln Jun 09 2016
Aspen to Buy Anesthetics From AstraZeneca for $520 Million Jun 09 2016
AstraZeneca sells rights to anaesthetics to South Africa's Aspen Jun 09 2016
South Africa's Aspen Pharmacare signs U.S. supply deal with ANI May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)